Poloxamer P85 increases anticancer activity of Schiff base against prostate cancer in vitro and in vivo

dc.authoridDede, Bülent/0000-0003-1416-7373
dc.authoridTelci, Dilek/0000-0002-2793-6533
dc.authoridDoğan, Ayşegül/0000-0003-4160-2270
dc.authoridbasak, nese/0000-0001-5566-8321
dc.authoridKilic, Ertugrul/0000-0001-6494-8923
dc.authoridDemirci, Selami/0000-0002-6174-1609
dc.authoridSahin, Fikrettin/0000-0003-1503-5567
dc.authorwosidDede, Bülent/HIZ-5767-2022
dc.authorwosidBeker, Mustafa Caglar/ABH-2222-2020
dc.authorwosidTelci, Dilek/N-5053-2019
dc.authorwosidDemirci, Selami/AAC-9963-2020
dc.authorwosidDoğan, Ayşegül/AAD-3223-2019
dc.authorwosidbasak, nese/ABH-5495-2020
dc.authorwosidKilic, Ertugrul/W-4563-2018
dc.contributor.authorDemirci, Selami
dc.contributor.authorDogan, Aysegul
dc.contributor.authorTurkmen, Nese Basak
dc.contributor.authorTelci, Dilek
dc.contributor.authorCaglayan, Ahmet B.
dc.contributor.authorBeker, Mustafa C.
dc.contributor.authorKilic, Ertugrul
dc.date.accessioned2024-08-04T20:43:12Z
dc.date.available2024-08-04T20:43:12Z
dc.date.issued2017
dc.departmentİnönü Üniversitesien_US
dc.description.abstractProstate cancer is the second most common cancer among men and the leading cause of death after lung cancer. Development of hormone-refractory disease is a crucial step for prostate cancer progression for which an effective treatment option is currently unavailable. Therefore, there is a need for new agents that can efficiently target cancer cells, decrease tumor growth, and thereby extend the survival of patients in late-stage castration-resistant prostate cancer. In the current study, a novel heterodinuclear copper(II)Mn(II) Schiff base complex combined with P85 was used to evaluate anticancer activity against prostate cancer in vitro and in vivo. Cell proliferation and cytotoxicity were evaluated by cell viability, gene, and protein expression assays in vitro. Results showed that the heterodinuclear copper(II)Mn(II) complex-P85 combination decreased cell proliferation by upregulating the apoptotic gene expressions and blocking the cell proliferation-related pathways. Tramp-C1-injected C57/B16 mice were used to mimic a prostate cancer model. Treatment combination of Schiff base complex and P85 significantly enhanced the cellular uptake of chemicals (by blocking the drug transporters and increased life time), suppressed tumor growth, and decreased tumor volume steadily over the course of the experiments. Overall, heterodinuclear copper(II) Mn(II) complex-P85 showed remarkable anticancer activity against prostate cancer in in vitro and in vivo. Anti-Cancer Drugs 28: 869-879 Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.en_US
dc.description.sponsorshipYeditepe Universityen_US
dc.description.sponsorshipThis study was funded by Yeditepe University.en_US
dc.identifier.doi10.1097/CAD.0000000000000528
dc.identifier.endpage879en_US
dc.identifier.issn0959-4973
dc.identifier.issn1473-5741
dc.identifier.issue8en_US
dc.identifier.pmid28614092en_US
dc.identifier.scopus2-s2.0-85020738178en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage869en_US
dc.identifier.urihttps://doi.org/10.1097/CAD.0000000000000528
dc.identifier.urihttps://hdl.handle.net/11616/97858
dc.identifier.volume28en_US
dc.identifier.wosWOS:000408162400006en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofAnti-Cancer Drugsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectcastration-resistant prostate canceren_US
dc.subjectP85en_US
dc.subjectpoloxameren_US
dc.subjectprostate canceren_US
dc.subjectSchiff baseen_US
dc.titlePoloxamer P85 increases anticancer activity of Schiff base against prostate cancer in vitro and in vivoen_US
dc.typeArticleen_US

Dosyalar